Check 35,000+ stocks against 26 valuation models and 37 quality factors
Data-driven stock valuation
Which stocks are undervalued right now? Check free
Discover now →
Medicamen Biotech Limited (531146) fair value: what the stock is really worth
As of Oct 1, 2026: fair value of Medicamen Biotech Limited ₹65.85, price ₹315, upside -79.1%, quality 40 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.
- Fair value above price? No
- Good quality? No
- Add to watchlist
MB
Thin data
Sep 24, 2026
Medicamen Biotech Limited
531146 · BSEWeakest SetupStrongly overvalued and low quality.
!Fair value ₹65.85 · Strongly overvalued (−79.1%)
!Quality 40/100
!Expensive Growth (revenue 5y +5.3 %/yr)
✓Solidly profitable · 10.0% net margin (TTM)
✓Low debt
!0.2% dividend yield · Token dividend
!Narrow moat 41/100
!Evidence only low, so the estimate is less certain
Watch Medicamen Biotech Limited for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card.
Watch for free
Pro now: $1 first month
What runs behind every stock
26
valuation models
8 families, DCF to NCAV
37
quality factors
margins, balance sheet, cashflow, debt
6
AI factors
moat, what no ratio measures
2,000+
data points
verified, per stock, median
69 individual criteria per stock, every one traceable See the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Sep 24, 2026.
How to read this chart
60‑month range ₹221.85 – ₹1,192 · fair‑value band ₹43.46 – ₹65.85 · the ₹315.30 price screens above the ₹65.85 fair value. Dashed = 300-day average. As of Sep 24, 2026.
Company profile
Medicamen Biotech Limited manufactures and sells pharmaceutical formulations in India. The company offers its products in various forms, including tablets, capsules, liquid and dry syrups, ointments, and oral rehydration solutions. It also provides oral rehydration solution, mouth wash, and dental care products.
Show more
Medicamen Biotech Limited manufactures and sells pharmaceutical formulations in India. The company offers its products in various forms, including tablets, capsules, liquid and dry syrups, ointments, and oral rehydration solutions. It also provides oral rehydration solution, mouth wash, and dental care products. The company was founded in 1993 and is headquartered in New Delhi, India.
Stock analysis
Medicamen Biotech Limited (531146) currently trades at ₹315.30, while our model-based Fair Value estimate is ₹65.85, 79.1% below the price, so the stock looks overvalued today.
Show more
Valuation
Bull case: the DCF Models group reads highest at a median of ₹157.15 per share, and 0 of the 17 models we run sit above the ₹315.30 price.
Bear case: the Dividend Discount group reads lowest at ₹14.61, and 17 of the 17 models stay below the price. Evidence for this calculation is low.
Scenario range: ₹43.46 (bear) to ₹65.85 (bull), the price of ₹315.30 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 40/100 (below-average quality), in the Healthcare sector.
Expensive Growth: The company is growing, but growth may require heavy reinvestment or weak cash conversion.
Medicamen Biotech Limited reported revenue of ₹1.6B in FY2025 versus ₹1.1B in FY2021, a compound +9.6%/yr. Reported net income was ₹71.1M in FY2025, compounding −12.5%/yr from FY2021.
Key figures
Market cap ₹4.8B (≈ $50.0M) · P/E ratio 37.5 · P/S ratio 1.64 · EPS (TTM) ₹10.03 · Dividend yield 0.2% · Net margin 4.4% · Return on assets (EBIT) 6.1% · Operating margin 12.7%.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 32 out of 100 (medium confidence).
What moves the price
The share trades about 24% below its 52-week high and 42% above its 52-week low, currently above its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at −10% fair-value upside, at −79%, 531146 screens richer than that median.
Fair Value models
Bear ₹43.46
Fair Value ₹65.85
Bull ₹65.85
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model. Based on fiscal year 2025 figures (about 12 months old). Earnings retained since then (₹9.53 per share) are deliberately not added.
Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds.
Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Highest evidence
Owner Earnings
₹104.67
₹157.15
₹233.21
76
Residual Income
₹125.53
₹120.96
₹122.94
76
EPV
₹26.42
₹30.41
₹33.85
74
All 17 models by family
DCF Models
Owner Earnings
₹104.67
₹157.15
₹233.21
76
Earnings-Based
Graham-Dodd
₹39.57
₹118.56
₹157.08
65
Lynch FV
₹25.13
₹35.90
₹46.67
61
PEG = 1.0
₹25.13
₹35.90
₹46.67
57
EPV
₹26.42
₹30.41
₹33.85
74
Dividend Discount
Gordon GGM
₹9.14
₹18.21
₹27.58
67
DDM Multi-Stage
₹9.14
₹14.61
₹19.23
66
Multiples
P/E Multiple
₹96.00
₹128.01
₹160.01
63
P/S Multiple
₹74.19
₹98.91
₹123.64
58
P/B Multiple
₹74.19
₹98.91
₹123.64
55
EV/EBIT
₹72.03
₹95.66
₹119.29
66
EV/EBITDA
₹118.92
₹158.17
₹197.43
67
EV/Revenue
₹51.74
₹73.42
₹95.11
54
Asset-Based
NCAV (Graham)
₹87.20
₹116.85
₹174.40
54
Economic Profit
Residual Income
₹125.53
₹120.96
₹122.94
76
ROIC Compounder
₹26.42
₹30.41
₹33.85
72
Growth Earnings
Growth-Adj P/E
₹78.00
₹111.43
₹144.86
67
Notify me when 531146 reaches fair value
Put 531146 on your watchlist. We get in touch as soon as price and fair value meet or the trend turns.
Set up alert →Quality Score breakdown
Overall quality
40/100
Of which business quality 39 · Market factors (momentum, volatility) 28
Profitability
31
Margins and returns on capital today
Quality Growth
22
Are margins and returns improving?
Cashflow
0
Earnings quality: real cash, not paper profit
Fin. Strength
61
Balance sheet, leverage, solvency risk
Investment
62
Disciplined investing over empire-building
Low Volatility
11
Calm price path (market factor)
Momentum
34
Price trend over the last 3–12 months (market factor)
52W Momentum
35
Distance to the 52-week high (market factor)
Net Issuance
72
Share count: buybacks or dilution?
Revenue & earnings trend
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.
37/100
The company is growing, but growth may require heavy reinvestment or weak cash conversion.
Revenue growth 1 year
−9.3%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+12.1%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+5.3%
Start year 2020 (pandemic). Over 10 years: +7.6% a year
Revenue growth 11 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+7.5%
’14
’15
’16
’17
’18
’19
’20
’21
’22
’23
’24
’25
What shareholders gained per year (last 5 years), in INR ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate. Measured in INR: this currency has depreciated against the euro and dollar over the long run, so part of the nominal rate is currency erosion that never reaches a EUR/USD investor.
−11.3%
Earnings growth per share plus dividend.
Earnings per share, growth per year−11.5%
Dividend (yield on the price)0.2%
Profit margin 2020 to 2025 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.13% → 4%
531146 screens overvalued: fair value 79% below the price. Compare with Anuh Pharma Limited →
Compare Medicamen Biotech Limited with another stock
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its sector: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median. (Industry “Drugs - Generic” was too small, so the broader sector is used.)Health Care · 2434 stocks
Beats the sector median on 3/12 measures
Overall it trails its sector peers.
Valuation Multiplesvs Health Care median · lower = cheaper
Context: sector, industry, market
- Is the Health Care sector expensive or cheap?
- P/E, EV/EBITDA and margins by industry (reference tables)
- Undervalued stocks: Indian Stocks
- Valuation of the India market
Values & ESG
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
None of the checked exposures detected
Similar stocks
10 more Drugs - Generic stocks, each showing price versus our Fair Value estimate.
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Anuh Pharma Limited 506260 | ₹86.88 | ₹30.19 | −65% |
| Eli Lilly and Company LLY | $1,157 | $749.08 | −35% |
| Johnson & Johnson, JNJ | $264.74 | $168.85 | −36% |
| AbbVie Inc ABBV | $261.59 | $259.62 | −1% |
| Roche Holding RO | CHF 375.20 | CHF 326.56 | −13% |
| Merck & Co MRK | $143.81 | $129.26 | −10% |
| UnitedHealth Group UNH | $367.08 | $295.49 | −20% |
| Novartis AG NOVN | CHF 118.06 | CHF 121.90 | +3% |
| Thermo Fisher Scientific Inc TMO | $675.05 | $686.04 | +2% |
| Amgen Inc AMGN | $421.51 | $463.66 | +10% |
Explore undervalued stocks
More undervalued Healthcare stocks →
All undervalued stocks
TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend Stocks
Try a ready-made strategy
Pick a strategy and jump into the live analysis with that exact screen applied.
🥇 Backtested Best
🏆 Big Names
⭐ Top Rated
💎 Quality on Sale
🚀 Profitable Growth
🧊 Quality Compounders
💵 Dividend Stars
📈 Strong Momentum
📉 Fallen Angels
⚖️ Deeply Undervalued
🔍 Small-Cap Gems
🏰 Moat at a Fair Price
💼 Insider Buying
🎩 Buffett-Style Quality
📚 Peter Lynch GARP
🧮 Greenblatt Magic Formula
🛡️ Graham Defensive
Discover tools
Stock screenerFilter by region, size and sector
Compare toolTwo stocks side by side
Extrinsic Value Calculator…Calculator with industry benchmark
Peter Lynch Fair Value Formula &…Calculator with industry benchmark
Run the numbers yourself: free valuation calculators
Frequently asked questions
Is Medicamen Biotech Limited (531146) overvalued or undervalued?
As of Sep 24, 2026, our model estimates a fair value of ₹65.85 versus a price of ₹315.30, about −79% upside (overvalued).
What is the fair value of 531146?
Our model-based fair value for Medicamen Biotech Limited is ₹65.85 (as of Sep 24, 2026), built from audited fundamentals. The current price: ₹315.30.
What is the quality score of 531146?
Medicamen Biotech Limited has a Quality Score of 40/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Medicamen Biotech Limited (531146)?
Our model-based price target is the fair value of ₹65.85 (as of Sep 24, 2026) from 17 valuation models. Cautious scenario ₹43.46, optimistic scenario ₹65.85. It is a calculation from audited fundamentals, not an analyst target.
What is the Medicamen Biotech Limited stock forecast for 2026?
Our models put fair value at ₹65.85, about −79% upside versus a price of ₹315.30 (overvalued). Cautious scenario ₹43.46, optimistic scenario ₹65.85. The calculation is refreshed regularly with new filings.
What is the revenue of Medicamen Biotech Limited (531146)?
Medicamen Biotech Limited reported trailing-twelve-month revenue of about ₹1.2B (latest available figure, as of Sep 24, 2026).
Does Medicamen Biotech Limited pay a dividend?
Medicamen Biotech Limited currently shows a dividend yield of about 0.16% relative to its recent price (as of Sep 24, 2026).
What is the intrinsic value of Medicamen Biotech Limited (531146)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Medicamen Biotech Limited it is ₹65.85 per share (as of Sep 24, 2026), against a price of ₹315.30. It is the blended result of 17 valuation models (cash flow, earnings, asset, dividend).
Is Medicamen Biotech Limited stock overvalued or undervalued in 2026?
As of Sep 24, 2026, 531146 trades above its calculated fair value: price ₹315.30, fair value ₹65.85, a gap of about −79% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 531146?
No. The price is what the market pays today (₹315.30); the fair value is what the company's own numbers justify (₹65.85). For Medicamen Biotech Limited the two are ₹249.45 per share apart. That gap is exactly why we show both numbers side by side.
How much is Medicamen Biotech Limited worth?
The market values Medicamen Biotech Limited at about ₹4.8B (market capitalisation, as of Sep 24, 2026). Per share that is ₹315.30; our models calculate a fair value of ₹65.85 per share.
What do the bullish and bearish scenarios say about 531146?
Our models span a range for Medicamen Biotech Limited: cautious scenario ₹43.46, base ₹65.85, optimistic ₹65.85 per share (as of Sep 24, 2026, price ₹315.30). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of 531146?
Medicamen Biotech Limited trades at a price-to-earnings ratio of 37.5 (as of Sep 24, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of ₹65.85 is built from several models across several years. Other multiples: P/B 2.3, P/S 3.9, EV/EBITDA 26.8.
How solid is the balance sheet of Medicamen Biotech Limited (531146)?
Balance-sheet figures for Medicamen Biotech Limited (as of Sep 24, 2026): debt of 0.01 per unit of equity. They feed the Quality Score of 40/100, which measures business quality independently of the share price.
How far is 531146 from its 52-week high?
Medicamen Biotech Limited trades at ₹315.30, about 24% below its 52-week high of ₹416.70 and 42% above the low of ₹221.85 (as of Oct 1, 2026). Distance from the high says nothing about value: that is what the fair value of ₹65.85 is for.
Which stocks are comparable to Medicamen Biotech Limited?
From the same area (Healthcare) we also value Anuh Pharma Limited, Eli Lilly and Company, Johnson & Johnson,, AbbVie Inc, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Medicamen Biotech Limited stock attractive at the current price?
The data as of Sep 24, 2026: price ₹315.30, calculated fair value ₹65.85 (−79%), Quality Score 40/100, from 17 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of 531146 calculated?
We run Medicamen Biotech Limited through 17 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of ₹65.85, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 14.5 % above its aggregate fair value. Medicamen Biotech Limited itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Medicamen Biotech Limited (531146)?
The closing price on Oct 1, 2026 was ₹315.30. Our model-based fair value is ₹65.85, about −79% upside (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Medicamen Biotech Limited right now?
The price sits above even our optimistic bull case (₹65.85). The favourable scenario is already priced in. Weak quality (40/100) and above fair value at the same time, the margin of safety is missing on both counts. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution.
Key figures of Medicamen Biotech Limited
How large is the market capitalisation of Medicamen Biotech Limited (531146)?
The market capitalisation of Medicamen Biotech Limited is ₹4.8B (≈ $50.0M). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Medicamen Biotech Limited (531146)?
The price-to-sales ratio of Medicamen Biotech Limited is 1.64 (P/E × margin). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Medicamen Biotech Limited (531146)?
Earnings per share at Medicamen Biotech Limited are ₹10.03 (price ÷ EPS = P/E 37.5). Earnings per share over the last twelve months: total profit spread across every single share.
What is the dividend yield of Medicamen Biotech Limited (531146)?
The dividend yield of Medicamen Biotech Limited is 0.2% (payout 5.0%). Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.
What is the net margin of Medicamen Biotech Limited (531146)?
The net margin of Medicamen Biotech Limited is 4.4% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the EBIT return on assets of Medicamen Biotech Limited (531146)?
On an EBIT basis the return on assets of Medicamen Biotech Limited is 6.1% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Medicamen Biotech Limited (531146)?
The operating margin of Medicamen Biotech Limited is 12.7% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Medicamen Biotech Limited (531146)?
Revenue at Medicamen Biotech Limited is growing −10.7% versus a year earlier (3y avg +12.1%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Medicamen Biotech Limited (531146)?
Earnings per share at Medicamen Biotech Limited are growing −33.1% versus a year earlier. How much earnings per share grew versus a year earlier.
Free · no account needed
Watch Medicamen Biotech Limited in the live analysis
One click puts Medicamen Biotech Limited on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.
Watch for free →Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.